SCHEMBL3015682

SCHEMBL3015682

Cc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.54
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.54
ALDH1A1 P00352 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
POLB P06746 1/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.54
AR P10275 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
TSHR P16473 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009782 0.94 AR (0.55) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3010853 0.92 AR (0.47) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3008001 0.92 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3007949 0.92 AR (0.60) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3017092 0.91 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3010614 0.90 AR (0.51) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3015811 0.90 MAPK1 (0.52) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3019911 0.90 SMN1; SMN2 (0.63) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3016248 0.89 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL3015877 0.89 AR (0.47) SMN1; SMN2RAB9ANPC1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.